Regeneron Pharmaceuticals Inc
REGN
View Detailed Chart
560.000USD
-8.200-1.44%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
59.58BMarket Cap
13.36P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.44%
5 Days
-2.33%
1 Month
-1.05%
6 Months
-16.03%
Year to Date
-21.38%
1 Year
-51.45%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
28
analysts
Buy
Current Rating
730.349
Target Price
+30.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.67% year-on-year.
Undervalued
The company’s latest PE is 13.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 99.72M shares, decreasing 2.00% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.37M shares of this stock.
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEODr. Leonard S. Schleifer, M.D., Ph.D
Websitehttps://www.regeneron.com/
Related Instruments
-0.12%
-0.25%
-0.85%
-1.90%
-2.80%
-2.75%
+1.05%
-2.24%
-2.81%
-3.98%
-1.30%
-0.71%
-2.82%
-1.16%
-0.61%
-1.57%
+0.03%
-1.60%
-0.57%
-0.15%
